Epidermal Growth Factor Receptor-targeted Immunophotodiagnosis and Photoimmunotherapy of Oral Precancer in Vivo

Nikolaos S. Soukos, Michael R. Hamblin, Suzanne Keel, Richard L. Fabian, Thomas F. Deutsch, and Tayyaba Hasan

ABSTRACT

Immunophotodiagnosis uses a fluorescence-labeled monoclonal antibody (MAb) that recognizes a tumor-associated antigen to image the fluorescence emitted from the fluorophore-bound MAb that has localized in the tissue. It may be used to diagnose malignant or precancerous lesions, to delineate the margins for tumor resection, or as a feedback mechanism to assess response to treatment. In oral precancer, the epidermal growth factor receptor (EGFR) is overexpressed and could be used as a marker for early detection or as a target for therapy. The goal of this study was to test an anti-EGFR MAb (C225) coupled to either the near-infrared fluorescent dye N,N'-di-carboxypentyl-indodicarbocyanine-5,5'-disulfonic acid for detection or a photochemically active dye (chlorin<sub>e6</sub>) for therapy of early premalignancy in the hamster cheek pouch carcinogenesis model. Fluorescence levels in the carcinogen-treated tissue correlated with the histological stage of the lesions when the C225-N,N'-di-carboxypentyl-indodicarbocyanine-5,5'-disulfonic acid conjugate was used but did not do so with the irrelevant conjugates. Discrete areas of clinically normal mucosa with high fluorescence (hot spots) were subsequently shown by histology to contain dysplastic areas. The best contrast between normal and carcinogen-treated cheek pouches was found at 4–8 days after injection. To test the potential of immunophotodiagnosis as a feedback modality for therapeutic intervention, experiments were conducted with the same MAb conjugated to chlorin<sub>e6</sub> followed by illumination to reduce expression of the EGFR by a photodynamic effect. Subsequent immunophotodiagnosis showed that this treatment led to a significant reduction in fluorescence in the carcinogen-treated cheek pouch compared with nonilluminated areas. This difference between illuminated and dark areas was not seen in the normal cheek pouch. Taken together, the results demonstrate the potential for development of immunophotodiagnosis as a diagnostic tool and as a method of monitoring response to therapy and that the EGFR may be an appropriate target in head and neck cancer.

INTRODUCTION

Oral precancer includes all of the stages on the route to oral malignancy (1). It may represent a clinically unrecognized premalignant state arising against the background of clinically normal mucosa or a clinically recognizable premalignant lesion, either leukoplakia (white patch) or erythroplakia (red patch; Ref. 2). If oral precancer is not detected and treated early, then moderately advanced oral cancer at the time of diagnosis has a poor prognosis (2). A simple, safe, and effective treatment of early oral precancer should be noninvasive and should selectively destroy premalignant cells, leaving surrounding tissues undamaged.

Head and neck cancers including oral cancer and precancer (3–5) as well as other types of epithelial malignancies (6–9) overexpress the EGFR, a 170-kDa glycoprotein with an intrinsic tyrosine-specific protein kinase activity stimulated upon EGF binding (10). EGFR was found to be up-regulated in human normal oral epithelium adjacent to tumor and remained elevated throughout the progress from hyperplasia to dysplasia, and the expression was dramatically increased when dysplasia progressed to SCC (11). Significant EGFR overexpression was also detected in the chemically induced malignant transformation leading to carcinoma in the hamster cheek pouch model (12). These findings suggest that the overexpression of EGFR might be used as a marker for early diagnosis and treatment of oral precancer (13).

Anti-EGFR MAbs labeled with radioisotopes have been used for diagnosis of several types of cancers (14, 15). These MAbs have also been used with therapeutic intent and have been shown to lead to inhibition of tumor growth when administered alone (16) and to produce enhancement of the antitumor activity of chemotherapy (15, 17). MAbs coupled with fluorescent dyes, such as fluorescein (18, 19) and indocyanine (20), have also been used for diagnostic purposes. On the other hand, covalent conjugation of PSs, such as chlorins, to MAbs has been proposed to enhance the selectivity and efficacy of PDT for SCC in the hamster cheek pouch model (25).

Targeting the EGFR with antibody-delivered photoactive molecules may serve as a two-armed feedback-controlled approach: the PS together with illumination may destroy the EGFR and cause the premalignant lesion to regress, and the fluorescent dye may allow the progress of the treatment to be monitored. As a first step toward realizing this goal, the present study had two immediate aims: (a) to determine whether the i.v. injection of a conjugate between an anti-EGFR MAb (C225) and the fluorescent dye indocyanine Cy5.5 could deliver sufficient amounts of the fluorophore into clinically unrecognizable early premalignant lesions in the hamster cheek pouch carcinogenesis model to make them detectable by fluorescence imaging; and (b) to test the photodynamic effect of a conjugate between C225 and the PS Cy5.5, followed by illumination, in animals with early lesions and to examine the effect of the treatment on tissue levels of EGFR by the immunophotodiagnosis procedure after subsequent administration of C225-Cy5.5.

MATERIALS AND METHODS

Animal Model. Syrian golden hamster cheek pouch carcinogenesis closely replicates events involved in the development of premalignancy in human oral cancer (26). Male Syrian golden hamsters (Mesocricetus auratus; 80–100 g) were obtained from the Charles River Animal Research Facility (Boston, MA) at 4–6 weeks of age. Animals were housed four to a cage at room temperature with wood chips for bedding and a 12-h light/dark cycle. Water and laboratory chow were given ad libitum. All procedures received approval from the Subcommittee on Research Animal Care of Massachusetts General Hospital before the start of the study.

Epithelial changes characteristic of the progress to early premalignancy...
were induced by thrice weekly (Monday, Wednesday, and Friday) topical application using a Q-tip of 50–100 μl of a 0.5% solution of DMBA (Sigma Chemical Co., St. Louis, MO) in mineral oil on the right buccal pouch mucosa for 6 weeks. Initial studies also used 12 weeks of application of DMBA to give papillary tumors measuring 4–6 mm in diameter. Injection of drugs into the subcutaneous vein and immunophotodiagnosis and PIT studies were performed under i.p. anesthesia with a mixture of ketamine, xylazine, and atropine (80–100, 5–10, and 0.04 mg/kg, respectively). The hamsters were euthanized in a CO2 chamber. At the time of euthanasia, animals weighed between 180 and 220 g. After euthanasia, the cheek pouches were excised along with the underlying connective tissue and mucosal tissue, and routine histology (H&E staining) was performed.

**Chemicals.** The MAb C225 was kindly provided by ImClone Systems, Inc. (Somerville, NJ). Cy5.5 FluoroLink Dye (bifunctional NHS ester in sealed foil packets) was obtained from Amersham Life Science (Arlington Heights, IL). cgo was obtained from Porphyrin Products (Logan, UT). BSA and mouse IgG were obtained from Sigma Chemical Co.

**Preparation of Conjugates.** Cy5.5 conjugates were prepared by dissolving 2 mg of protein (C225, BSA, or mouse IgG) in 2 ml of 0.1 M sodium bicarbonate buffer (pH 9.3). The content of one Cy5.5 foil pack was dissolved in sodium bicarbonate buffer (200 μl) and added to the protein solution with shaking. The mixture was incubated in the dark at room temperature for 3 h, and then it was dialyzed three times against 5 liters of 0.01 M phosphate buffer (pH 7.4) to remove any unbound dye.

**In Vivo Fluorescence Imaging.** Imaging was conducted with a Pulnix room temperature CCD camera (model TM 745; Pulnix America, Inc., Sunnyvale, CA) with the anesthetized hamster placed on a movable stage approximately 50 cm below the camera. To avoid any reflectance, the cheek pouches were put on a black cloth covering a polystyrene platform and firmly attached to it using pins with a diameter of 100 μm. Each hamster was marked on both cheek pouches with Indian ink to give the maximum size rectangle possible within the exposed surface. The CCD camera was interfaced to an integration system (Pulnix) allowing integration of the signal for up to 1 s. The cheek pouches were illuminated with 670 nm light from an argon-ion (Innova 100; Coherent, Marlboro, MA) controlled by the computer program Global Lab Image (v2.20; Data Translation). The laser beam rested on each cheek pouch for 5 s to acquire each image; therefore, because the tissue was illuminated with 15 mW/cm2, it receives a fluence of 0.075 J/cm2 of energy. Each hamster was imaged before injection and on days 1, 2, 4, 6, and 8 after injection.

Each image series was analyzed by image analysis software (Global Lab Image v2.20). The India ink markings were visible on the fluorescence images as dark spots due to the absence of fluorescence. Two predefined regions were delineated for each hamster: (a) one covers the entire area between the India ink markings; and (b) the other covers the hot spot (if any) and was measured from the nearest two markings to be reproduced at each time point. The image analysis software gave the mean pixel intensity on a 256 gray-scale and the SD for each area. Measurements of average pixel intensity on the black background cloth surrounding the cheek pouch were taken for background correction. Each measurement of tissue fluorescence had the background measurement subtracted from it, yielding what is referred to as the absolute fluorescence.

**Immunophotodetection of Premalignant Lesions.** Before fluorescence imaging was undertaken, the cheek pouch mucosa was inspected and photographed to evaluate the lesions. Initial fluorescence imaging studies used three hamsters that had developed gross papillary tumors after 12 weeks of painting of the cheek pouch. These animals were injected with 670 μg of C225-Cy5.5 conjugate (the average Cy5.5:MAb ratio was 2.1:1) corresponding to 12 μg of Cy5.5 and imaged 2 days later. For imaging of oral premalignant lesions, 27 hamsters bearing lesions produced by painting the right cheek pouches for 6 weeks were studied. Nine hamsters were injected with C225-Cy5.5 as described above. Six control animals received 610 μg of irrelevant mouse IgG-Cy5.5 conjugate (the average Cy5.5:IgG ratio was 2:3:1) also corresponding to 12 μg of Cy5.5. Another group of six control animals was injected with 390 μg of BSA-Cy5.5 conjugate (the average Cy5.5:BSA ratio was 1.6:1) corresponding to 12 μg of Cy5.5 to distinguish between EGFR binding and increased vascular permeability. In all cases, the overall dose of Cy5.5 injected was 100 μg/kg body weight.

At the end of the fluorescence imaging studies, biopsies (approximately 25 mm2) were obtained to correlate the fluorescent signals with the histologically determined stage of the lesions. In the case of cheek pouches that showed a fluorescent hot spot, one biopsy was taken from the hot spot, and another was taken from a part of the cheek pouch distant from the hot spot. Tissue samples were immediately placed in 10% formalin followed by routine processing for paraffin embedding and histological study. Sections were stained with H&E and examined by light microscopy. **PIT in Vivo.** A pilot study investigated the photodynamic effect of the C225-cgo conjugate on EGFR expression in early premalignant lesions (6 weeks of DMBA treatment) of the hamster cheek pouch of 11 hamsters. Before injection of C225-cgo, the visible area of each cheek pouch (DMBA-treated and normal tissue) was divided in two equal parts using India ink, and the outer part of each cheek pouch to be exposed to light was marked, whereas the inner part was protected from light by a black cloth. Animals were injected with 3.38 mg of C225-cgo conjugate (the average cgo:MAb ratio was 4.8:1, corresponding to 65 μg of cgo), and 666 nm light was applied 2 days later (total fluence = 100 J/cm2). The effectiveness of the treatment was assessed by immunophotodiagnosis by injecting the C225-Cy5.5 conjugate as described above at 5 days posttreatment. Fluorescence imaging was performed 3 days after injection of the C225-Cy5.5 conjugate.
Statistics. SDs of ratios of two means were calculated by the use of addition in quadrature (29). The difference between two means was tested for significance by a two-sided Student’s t test, assuming equal or unequal variances as appropriate. Means of ratios were tested to see whether they were significantly >1 by one-sided Student’s t test.

RESULTS

Preparation and Characterization of Conjugates. The absorption spectra of the C225-Cy5.5 and BSA-Cy5.5 conjugates together with free Cy5.5 are shown in Fig. 1A. The conjugates have a distinct peak at 284 nm due to the protein absorbance by IgG and BSA, and the peak due to the Cy5.5 is at 675 nm for all conjugates. The number of dyes/protein molecule can be calculated assuming extinction coefficients of 2.5 × 10^5 M⁻¹ cm⁻¹ for Cy5.5 at 675 nm, 1.7 × 10^5 M⁻¹ cm⁻¹ for IgG (corrected for absorbance of Cy5.5 at 284 nm), and 1.2 × 10^5 M⁻¹ cm⁻¹ for BSA at 284 nm (likewise corrected for absorbance of Cy5.5). The C225-Cy5.5 conjugate had 2.1 molecules of Cy5.5 attached to each IgG, whereas BSA had 1.6 molecules/protein molecule.

Because the effectiveness of the c6 conjugates in the destruction of premalignant tissue may depend on the amount of PS able to be delivered to the lesion, it was desirable to have as high a loading of c6 as possible, consistent with the MAbs still retaining its immunoreactivity. In the present case, the loading of the c6 conjugates was limited by their tendency to aggregate when the ratio increased beyond 5 molecules c6/IgG. The absorption spectra of C225-c6 and free c6 are shown in Fig. 1B. The conjugate has a distinct absorbance at 284 nm due to the protein in the IgG, the intensity of the Soret band is somewhat reduced, and the long wavelength Q band is red shifted to 666 nm as opposed to 654 nm. It can be calculated assuming extinction coefficients of 1.5 × 10^5 mol⁻¹ cm⁻¹ for c6 at the Soret band and 2.4 × 10^5 mol⁻¹ cm⁻¹ for IgG at 280 nm. The C225-c6 conjugate had a loading of 4.8 molecules c6/IgG.

Fluorescence Localization in Living Cells. The fluorescence images of A431 and HCPC-1 cells that had been incubated with the conjugate at a final concentration of 0.1 μg of Cy5.5 equivalent in serum-containing medium for 3 h at 37°C are shown in Fig. 2, a and c, along with the corresponding bright-field images (Fig. 2, b and d). The conjugate showed a strong affinity for A431 cells, which was expected because these cells have a high number of EGFRs (30). In addition, a significant fluorescence was seen with HCPC-1 cells, indicating the suitability of the conjugate for targeting the DMBA tumor model. Neither cell line showed fluorescence after incubation with BSA-Cy5.5 or mouse IgG-Cy5.5 conjugates (data not shown).

Immunophotodiagnosis of Oral Precancer in Vivo. Initially, immunophotodiagnosis was performed on three animals with gross papillary tumors obtained after 12 weeks of painting of the cheek pouch with DBMA. Hamsters were injected with 670 μg of C225-Cy5.5 and imaged 2 days later. a, white-light image of both cheek pouches. b, fluorescence image of normal cheek pouch. c, fluorescence image of carcinogen-treated cheek pouch with papillary tumor (arrow); bar, 5 mm.

![Fig. 2. Fluorescence localization of C225-Cy5.5 with A431 and HCPC-1 cells.](image-url)

![Fig. 3. Fluorescence image of hamster with gross papillary tumor obtained after 12 weeks of painting of the cheek pouch with DBMA.](image-url)
Fig. 4. Fluorescence images of normal (a) and DMBA-treated (b) cheek pouches in hamster 6 at 6 days after the injection of the C225-Cy5.5 conjugate. Bar, 5 mm. A fluorescence hot spot (area of increased fluorescence) can be seen within the DMBA-treated cheek pouch (arrow). H&E histology shows (c) normal mucosal epithelium for the DMBA-untreated cheek pouch, (d) mild dysplasia for the DMBA-treated cheek pouch, and (e) moderate dysplasia for the hot spot.

Painted with DMBA for an average of 6 weeks. Animals were injected with C225-Cy5.5 or the control dye conjugates (mouse IgG-Cy5.5 or BSA-Cy5.5) and imaged on days 1, 2, 4, 6, and 8 after injection. A representative pair of images captured from the DMBA-treated and control cheek pouch in hamster 6 at 6 days after injection of C225-Cy5.5 is shown in Fig. 4. The mean values of the ratios of fluorescence of DMBA-treated cheek pouches:normal cheek pouches from groups of hamsters injected with the EGFR-targeted C225-Cy5.5 and nontargeted conjugates (mouse IgG-Cy5.5 and BSA-Cy5.5) are shown in Table 1. The ratios from the C225-Cy5.5 group were significantly greater than 1 for all time points except 1 day after injection. None of the control groups had mean ratios that were statistically $>1$. The histological diagnoses of the animals in the control groups were similar, with about 50% of the hamsters in each group showing focal dysplasia or hyperplasia.

Five of nine animals in the C225-Cy5.5 group showed a distinct and circumscribed area of increased fluorescence (termed a hot spot) within the overall increased fluorescence of the clinically normal DMBA-treated cheek pouch (see Fig. 4). The fluorescence values from these hot spots were calculated separately, and the resulting mean absolute values are plotted together with the overall (whole cheek pouch) mean absolute fluorescence values against time after injection in Fig. 5. The fluorescence intensities from the whole cheek pouches were highest 1 day after the injection of the C225-Cy5.5 conjugate (2 days after injection in the case of the hot spots) and then dropped in an apparent exponential decay.

Table 2 shows the correlation between the fluorescence ratios (DMBA-treated cheek pouches:normal cheek pouches) and the histological diagnosis of biopsies taken from whole (clinically normal) cheek pouches and from fluorescent hot spots located within cheek pouches of five hamsters. As can be seen, four of five of the hot spots showed evidence of dysplasia in the hot spot tissue, whereas only one (hamster 6) showed dysplasia outside of the hot spot. The remaining hot spot (hamster 3, which had the lowest fluorescence ratio) showed only hyperkeratosis and an inflammatory infiltrate.

**PIT Studies.** These experiments were performed to test the hypothesis that C225 could selectively deliver a PS to the EGFR in these early premalignant lesions and that after illumination, the resultant photodynamic effect would reduce the expression of the EGFR. Furthermore, immunophotodiagnosis could be used as a feedback tool for PIT, and the tissue fluorescence level may act as a surrogate marker for efficacy. We hypothesized that the effects of PIT on EGFR levels could be demonstrated by comparison of fluorescence images produced by C225-Cy5.5 in the cheek pouches at 5 days after treatment. A total of 11 hamsters had one cheek pouch painted with carcinogen for 6 weeks, and then each animal was injected with C225-Cy5.5. Three days later, part of each cheek pouch (carcinogen-treated and normal tissue) was illuminated with red light (100 J/cm²). Five days later, animals were injected with C225-Cy5.5 as described previously, and after another 3 days, fluorescence images were obtained. Four mean fluorescence values from the areas of cheek pouches were obtained and are shown in Table 3. As expected, there was a highly significant difference between the mean fluorescence values of the non-light-exposed areas of the normal and DMBA-treated cheek pouches (110 ± 21 versus 160 ± 29, $P < 0.0005$). The mean fluorescence values of the light-treated and non-light-treated areas of the normal cheek pouches were almost the same (112 ± 22 versus 110 ± 21). When the light-exposed DBMA-treated areas were compared with the non-light-exposed DMBA-treated areas, there was a significant reduction in fluorescence (124.2 ± 26 versus 160 ± 29, $P < 0.01$), and interestingly, there was no significant difference between the light-exposed DMBA-treated areas and either the light-exposed or the dark areas of the normal cheek pouches. This latter result suggests that the overexpression of the EGFR found after DMBA treatment had been reduced to background levels after PIT. After completion of the fluorescence imaging, the animals were sacrificed, and the cheek pouches were subjected to histological examination. All 11 hamsters had hyperkeratosis and focal hyperplasia in the DMBA-treated pouches, and 2 animals also had focal dysplasia. The light-exposed areas of both normal and DMBA-treated pouches also revealed a submucosal edema and inflammatory infiltrate.

**DISCUSSION**

The results obtained in this study show that the use of anti-EGFR MAb-targeted photoactive dyes may serve as a feedback-controlled optical diagnosis and therapy procedure for oral premalignant lesions.

The indocyanine dyes, such as the one used in the present study, have advantages over fluorescein, a dye that has been used for diagnostic purposes in both animal models (18) and humans (19). The longer wavelength emission penetrates tissue significantly better, and they have high fluorescence quantum yields and good solubility (31). More specifically, the indocyanine dye Cy5.5 emits a near-infrared fluorescence at 702 nm after excitation at 675 nm and has an extremely high molar absorption coefficient. These properties of Cy5.5

**Table 1** Ratios of fluorescence intensities from DMBA-treated and normal cheek pouches$^a$

<table>
<thead>
<tr>
<th>Time</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 4</th>
<th>Day 6</th>
<th>Day 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>C225-Cy5.5 (n = 9)</td>
<td>1.17 ± 0.25</td>
<td>1.19 ± 0.16</td>
<td>1.56 ± 0.51</td>
<td>1.54 ± 0.46</td>
<td>1.85 ± 0.44</td>
</tr>
<tr>
<td>IgG-Cy5.5 (n = 6)</td>
<td>1.01 ± 0.12</td>
<td>1.05 ± 0.12</td>
<td>1.07 ± 0.06</td>
<td>0.96 ± 0.09</td>
<td>0.99 ± 0.01</td>
</tr>
<tr>
<td>BSA-Cy5.5 (n = 6)</td>
<td>0.95 ± 0.18</td>
<td>0.98 ± 0.36</td>
<td>0.90 ± 0.15</td>
<td>0.96 ± 0.09</td>
<td>0.99 ± 0.01</td>
</tr>
</tbody>
</table>

$^a$ Ratios of mean fluorescence values (DMBA-treated cheek pouch:normal cheek pouch) from groups of hamsters at different time intervals after the injection of the specified conjugate. Values are means and SD calculated in quadrature.

$^b$ n.s., not significant.
should lead to increased sensitivity of detection of premalignant lesions because fluorescence from molecules localized deeper into tissue can be detected. Furthermore, background autofluorescence is minimized because the endogenous fluorophores present in tissue do not absorb at 675 nm (the excitation wavelength of Cy5.5). The C225-Cy5.5 conjugate used in this study, with a dye:MAb molar ratio of 2:1, was efficient in detection of oral premalignant lesions. Folli et al. (19) have also shown the suitability of an indocyanine-MAb conjugate with the same molar ratio for the detection of tumors in nude mice using the marker dye Cy5 with excitation and emission wavelengths of 640 and 667 nm, respectively. This indocyanine-MAb conjugate showed almost the same circulating half-life and tumor localization capacity as the unconjugated MAb (19).

The injection of the conjugate was well tolerated by the animals and produced a sufficiently bright fluorescence signal to allow quantitative imaging. At early time points (up to 24 h), the C225-Cy5.5 conjugate was distributed primarily within and near the vasculature. The same observations were also obtained using the BSA-Cy5.5 conjugate. Thus, fluorescence measurements in both DMBA-treated and normal cheek pouches showed average fluorescence intensity values with high SDs because fluorescence was obtained mainly from the cheek pouch capillaries. The microvascular changes observed in the cheek pouch capillary network 6 weeks after the first application of DMBA were similar to those observed by Lurie et al. (32) in the same model. Control cheek pouches contained a plexus of capillaries with uniform diameters that were connected to larger vessels, but the diameters of capillaries in DMBA-treated cheek pouches were larger than those of control cheek pouches. At 2 days postinjection, the fluorescence signal originated mainly from extravascular dye within the tissue. Although in a number of studies, immunophotodetection of malignant tumors was possible in animals and humans 24 h after the injection of either fluorescein (18, 19, 33)– or indocyanine-labeled (20, 31, 34) MABs, we did not observe any striking difference in fluorescence images obtained from control and premalignant tissue 24 h after the injection of the conjugate. There was some contrast between normal and premalignant tissue 2 days after the injection of the conjugate, but the best contrast was obtained at 4–8 days. The increase in contrast after 2 days is probably due to the relatively slow removal of nonspecifically bound MAb conjugate that has escaped from the vasculature into the tissue.

It has been reported that certain types of tumor vasculature have a dramatically increased permeability to macromolecules (35, 36). This increased permeability has been reported (37) to account for some of the tumor-localizing ability of MAb conjugates. In the present study, a BSA-Cy5.5 conjugate was used to test the possibility of a nonspecific macromolecule giving increased fluorescence in the lesions due to preferential extravasation. Hyperpermeability of blood vessels in premalignant lesions may not be the case here because these lesions were very early. Our fluorescence imaging system could distinguish between premalignant lesions and normal mucosa, and in addition, dysplastic areas could be detected as fluorescent hot spots. Histopathological examination of excised tissue from these areas dem-

Table 2. Ratios of fluorescence intensities from DMBA-treated and normal cheek pouches in individual animals injected with C225-Cy5.5 Ratios of fluorescence values (DMBA-treated cheek pouch:normal cheek pouch) from individual hamsters at different time intervals after the injection of the C225-Cy5.5 conjugate correlated with the histologically determined stage of the premalignant lesion. Values are means and SD calculated in quadrature.

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 4</th>
<th>Day 6</th>
<th>Day 8</th>
<th>Microscopic diagnosis from H&amp;E-stained fixed slides</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.2</td>
<td>1.13</td>
<td>1.53</td>
<td>1.16</td>
<td></td>
<td>Hyperkeratosis</td>
</tr>
<tr>
<td>2</td>
<td>1.06</td>
<td>1.05</td>
<td>1.09</td>
<td>0.92</td>
<td></td>
<td>Hyperkeratosis</td>
</tr>
<tr>
<td>3a</td>
<td>0.94</td>
<td>1.05</td>
<td>1.08</td>
<td>1.23</td>
<td>1.33</td>
<td>Hyperkeratosis</td>
</tr>
<tr>
<td>4</td>
<td>1.23</td>
<td>1.16</td>
<td>1.23</td>
<td>1.02</td>
<td>1.49</td>
<td>Hyperkeratosis</td>
</tr>
<tr>
<td>5</td>
<td>0.94</td>
<td>1.07</td>
<td>1.07</td>
<td>1.9</td>
<td>2.3</td>
<td>Hyperkeratosis</td>
</tr>
<tr>
<td>6a</td>
<td>1.06</td>
<td>1.13</td>
<td>2</td>
<td>2.18</td>
<td>1.56</td>
<td>Dysplasiaa</td>
</tr>
<tr>
<td>7a</td>
<td>1.76</td>
<td>1.48</td>
<td>2.09</td>
<td>1.74</td>
<td>2.23</td>
<td>Hyperkeratosis, hyperplasia</td>
</tr>
<tr>
<td>8a</td>
<td>1.17</td>
<td>1.24</td>
<td>2.45</td>
<td>1.99</td>
<td></td>
<td>Hyperkeratosis</td>
</tr>
<tr>
<td>9a</td>
<td>1.17</td>
<td>1.43</td>
<td>1.48</td>
<td>1.68</td>
<td>2</td>
<td>Hyperkeratosis</td>
</tr>
</tbody>
</table>

B. Fluorescence ratios from hot spot (hot spot:normal cheek pouch) Microscopic diagnosis from hot spot

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 4</th>
<th>Day 6</th>
<th>Day 8</th>
<th>Microscopic diagnosis from hot spot</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>1.55</td>
<td>1.57</td>
<td>1.87</td>
<td>2.02</td>
<td></td>
<td>Hyperkeratosis, strong inflammatory infiltrate</td>
</tr>
<tr>
<td>6</td>
<td>2.3</td>
<td>3.31</td>
<td></td>
<td></td>
<td></td>
<td>Dysplasiaa</td>
</tr>
<tr>
<td>7</td>
<td>2.35</td>
<td>2.68</td>
<td>2.4</td>
<td>3.38</td>
<td></td>
<td>Dysplasiaa</td>
</tr>
<tr>
<td>8</td>
<td>1.63</td>
<td>1.84</td>
<td>3.54</td>
<td>2.66</td>
<td></td>
<td>Dysplasiaa</td>
</tr>
<tr>
<td>9</td>
<td>1.45</td>
<td>1.86</td>
<td>1.63</td>
<td>1.87</td>
<td>2.48</td>
<td>Dysplasiaa</td>
</tr>
</tbody>
</table>

Mean ± SD 1.54 ± 0.13 <0.0005   1.54 ± 0.13 <0.0001 1.54 ± 0.13 <0.0005 1.54 ± 0.13 <0.0005

Ps for mean > 1

a Areas with DMBA-treated cheek pouches that showed an increased fluorescence signal (hot spots) were found.

b Hyperkeratosis, hyperplasia, and drop-shaped rete processes.

c Hyperkeratosis, irregular epithelial downgrowth, loss of basal cell polarity, increased nuclear:cytoplasmic ratio, and a small number of abnormal mitoses.

d Hyperkeratosis, irregular epithelial downgrowth, and loss of basal cell polarity.

eg Hyperkeratosis, hyperplasia, nuclear hyperchromatism, and strong inflammatory infiltrate.

f Hyperkeratosis, hyperplasia, irregular epithelial downgrowth, deep cell keratinization, and enlarged prickle cells.
onstrated the presence of dysplasia. This suggests that different levels of the C225-Cy5.5 conjugate were retained in lesions at different stages of carcinogenesis, reflecting increased numbers of EGFRs in dysplastic lesions. Other workers have used PSs designed for PDT to carry out fluorescence diagnosis of premalignant lesions in the hamster cheek pouch. These PSs include Photofrin (38, 39) and 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (40), and the free dye fluorescein has also been used (41). However, Andrejevic Blant et al. (42) failed to detect any increased fluorescence in premalignant lesions using the PS benzoporphin derivative or tetra(m-hydroxyphenyl)chlorin.

The apparent significance of the EGFR in human cancer has prompted several efforts to use it as a therapeutic target. Several murine MAbs that bind and block the binding of ligand to EGFRs were able to inhibit the proliferation of a variety of human cancer cell lines in culture and in xenograft tumor models (43). A link between EGFR signaling and angiogenesis has recently been identified (44). It has been reported that systemic administration of MAb C225 inhibited the growth and metastasis of human transitional cell carcinoma established in the bladder wall of athymic nude mice in part by inhibition of angiogenesis (45). The use of conjugates between an anti-EGFR MAb and a PS to target photodynamic treatment to the EGFR is an approach with many advantages. It combines the specificity of the MAb with the spatial confinement of light delivery in which damage will be limited to the irradiated volume of tissue and should reduce side effects. In addition, these photoinmunoconjugates do not necessarily need to be internalized to impose their effect. Photodestruction of EGFRs should result in a more lasting reduction of growth signals in the nucleus than merely blocking the binding of EGF. The ultimate goal of this treatment is the inhibition of cellular proliferation, and additional studies should follow the progression of the animals’ lesions over time. The photodynamic effects of a conjugate between an anti-EGFR MAb and the PS benzoporphin derivative have been studied on SCC in the hamster cheek pouch model (25). The conjugate was effective for PDT, producing an 80% rate of complete response.

In conclusion, our results suggest that immunophotodiagnosis using C225-Cy5.5 may have potential both as a diagnostic modality for oral precancer and as a surrogate marker for disease progression. The use of a near-infrared emitting fluorochrome as a label may be an alternative to using radioisotopes, with consequent increased patient safety. To extend the analogy with radioisotopes, the principle of using an anti-EGFR MAb to deliver phototoxic molecules applies equally well to therapeutic PSs as to fluorophores, and furthermore, immunophotodiagnosis can be used to assess response. Additional studies should correlate the histology and long-term tissue response of dysplastic lesions, with the immunofluorescence signals obtained in both treated and control lesions. Mechanistic studies to identify the site at which the actual damage is inflicted and to investigate the repair of the signaling pathway should also be conducted.

## REFERENCES

EGFR IMMUNOPHOTODIAGNOSIS OF ORAL PRECANCER


Epidermal Growth Factor Receptor-targeted Immunophotodiagnosis and Photoimmunotherapy of Oral Precancer in Vivo

Nikolaos S. Soukos, Michael R. Hamblin, Suzanne Keel, et al.

Cancer Res 2001;61:4490-4496.

Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/11/4490

Cited articles  This article cites 38 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/11/4490.full#ref-list-1

Citing articles  This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/61/11/4490.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.